ANIXA BIOSCIENCES INC

CEO Kumar Amit keeps buying Anixa Biosciences shares, boosting confidence in its cancer‑diagnostics pipeline and hinting at a valuation rebound.

Inside insider buying signals optimism for Anixa Biosciences (ANIXA); executives acquire shares amid a diagnostic pipeline boost and market dip.

CEO Kumar Amit keeps buying Anixa Biosciences shares despite volatility, signaling confidence in future CAR‑T and vaccine breakthroughs.

Insider buys signal confidence in Anixa Biosciences—Baskies Arnold’s recent purchase at $3.13 and CEO’s massive stake suggest the stock may still have upside.

CEO Amit Kumar’s latest 5,000‑share purchase at $3.44 signals growing confidence in Anixa Biosciences’ cancer diagnostics pipeline and may hint at future value unlocking.

CEO of Anixa Biosciences buys shares at $3.46, showing leadership confidence in the diagnostics pipeline and potential upside for investors.

Insider buying at Anixa Biosciences shows strong confidence in its breast‑cancer vaccine pipeline and new patents – a potential entry point for long‑term investors.

Insider buying spikes at Anixa Biosciences reveal confidence in its breast‑cancer vaccine pipeline and Mexican patent—steady growth potential amid quiet market.

Insider buying at Anixa Biosciences shows leadership confidence—executives are purchasing shares amid a volatile valuation, hinting at future growth potential.